LGND Ligand Pharmaceuticals Inc - Class B

Price (delayed)

$287.07

Market cap

$5.75B

P/E Ratio

36.34

Dividend/share

N/A

EPS

$7.9

Enterprise value

$6.09B

?
Relative Growth: Rel. Growth: 79
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: 49
Relative Profitability: Rel. Profitability: 98

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model ...

Highlights
The gross profit has surged by 55% year-on-year and by 3.1% since the previous quarter
The revenue has surged by 51% year-on-year and by 2.4% since the previous quarter
Ligand Pharmaceuticals Inc - Class B's quick ratio has decreased by 3.3% QoQ

Key stats

What are the main financial stats of LGND

LGND stock price

How has the Ligand Pharmaceuticals Inc - Class B stock price performed over time
Intraday
-0.16%
1 week
-3.51%
1 month
-10.16%
1 year
116.3%
YTD
51.83%
QTD
-9.18%

Financial performance

How have Ligand Pharmaceuticals Inc - Class B's revenue and profit performed over time
Revenue
$274.48M
Gross profit
$261.5M
Operating income
$94.59M
Net income
$153.56M
Gross margin
95.3%
Net margin
55.9%
The net margin has soared by 176% YoY and by 20% from the previous quarter
The company's operating income has surged by 131% QoQ
Ligand Pharmaceuticals Inc - Class B's operating margin has surged by 125% QoQ
The gross profit has surged by 55% year-on-year and by 3.1% since the previous quarter

Price vs fundamentals

How does LGND's price correlate with its fundamentals

Growth

What is Ligand Pharmaceuticals Inc - Class B's growth rate over time

Valuation

What is Ligand Pharmaceuticals Inc - Class B stock price valuation
P/E
36.34
P/B
5.74
P/S
20.8
EV/EBIT
31.97
EV/EBITDA
27
EV/Sales
22.19
Ligand Pharmaceuticals Inc - Class B's EPS has increased by 23% QoQ
LGND's P/B is 140% higher than its 5-year quarterly average of 2.4 and 64% higher than its last 4 quarters average of 3.5
The equity has grown by 25% year-on-year
The price to sales (P/S) is 108% higher than the 5-year quarterly average of 10.0 and 55% higher than the last 4 quarters average of 13.4
The revenue has surged by 51% year-on-year and by 2.4% since the previous quarter

Efficiency

How efficient is Ligand Pharmaceuticals Inc - Class B business performance
The company's return on equity has surged by 199% YoY and by 17% QoQ
Ligand Pharmaceuticals Inc - Class B's return on sales has surged by 180% YoY and by 14% QoQ
The ROA has soared by 177% YoY and by 9% QoQ
Ligand Pharmaceuticals Inc - Class B's ROIC has soared by 146% YoY but it has decreased by 9% from the previous quarter

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals Inc - Class B financials performed over time
The company's total assets is 186% higher than its total liabilities
The company's total assets has surged by 69% YoY
LGND's current ratio is down by 4.3% since the previous quarter
The debt is 55% less than the equity
The equity has grown by 25% year-on-year
The debt to equity has grown by 2.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.